ArticleCancers2023
Outcomes of Radiofrequency Ablation for Solitary T1a Renal Cell Carcinoma: A 20-Year Tertiary Cancer Center Experience.
Article in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- Percutaneous Cryoablation of Clinical T1b Renal Tumors: A Tertiary Cancer Center Experience.Cardiovascular and interventional radiology · 2026Observational
- Perioperative outcomes after Robot-assisted partial nephrectomy for very small (≤ 2 cm) versus larger small (> 2-4 cm) renal tumors: a multi-institutional propensity score-matched study.Journal of robotic surgery · 2026Article
- Long-term Clinical Outcomes of Radiofrequency Ablation for Pathologically Diagnosed T1a Renal Cell Carcinoma: A 10-Year Single-center Experience.Interventional radiology (Higashimatsuyama-shi (Japan) · 2026Article
- Percutaneous radiofrequency ablation of pancreatic insulinoma: A case report and literature review.Radiology case reports · 2025Article
- Shifting paradigms in the treatment of small renal masses.Translational andrology and urology · 2025Article
- Technique and Outcomes of Radiofrequency Ablation of Biopsy-Proven 3-4 cm T1a Renal Cell Carcinoma.Biomedicines · 2025Article
- Use of Radiofrequency in Robot-Assisted Partial Nephrectomy for Small Tumors: A Novel Technique.Current oncology (Toronto, Ont.) · 2025Article
- Current use of percutaneous ablation in renal tumors: an analysis of the registry of the German Society for Interventional Radiology and Minimally Invasive Therapy.European radiology · 2025Article
- Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.World journal of radiology · 2025Review
- Fiber Bragg Grating Thermometry and Post-Treatment Ablation Size Analysis of Radiofrequency Thermal Ablation on Ex Vivo Liver, Kidney and Lung.Sensors (Basel, Switzerland) · 2025Article
- Review
- The long-term outcomes of local tumor destruction versus partial nephrectomy for cT1a non-clear cell renal cell carcinoma and development of prognostic nomograms.Journal of cancer research and clinical oncology · 2024Article
- Special Issue Editorial: Emerging Therapies in Renal Cell Carcinoma: The Road to a Cure?Cancers · 2023Article
- The Judicious Use of Stereotactic Ablative Radiotherapy in the Primary Management of Localized Renal Cell Carcinoma.Cancers · 2023Review
- Risk-adjusted trifecta outcomes in ultrasound-guided RFA of T1a renal masses: experi-ence from a large tertiary cancer center.International braz j urol : official journal of the Brazilian Society of UrologyArticle
- Interventional oncology: A primer for clinicians on the role of ablation and embolization for solid tumors.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe aim is to determine the long-term oncologic and survival outcomes of the radiofrequency ablation (RFA) of solitary de novo T1a renal cell carcinoma (RCC). MATERIALS AND
methodsWe retrospectively reviewed our renal ablation registry and included only patients with new solitary, biopsy-proven T1a RCC (<4 cm) who underwent RFA from January 2001 through December 2020. We collected patient and tumor characteristics. Survival rates were estimated using the Kaplan-Meier method.
resultsOf the 243 patients who met our inclusion criteria (160 male and 83 female, median age 68 years), 128 (52.6%) had another primary malignancy other than renal malignancy. Two-hundred forty-three RFA procedures were performed for 243 renal tumors of a median tumor size of 2.5 cm. The median follow-up period was 3.7 years. Most tumors (68.6%) were clear cell RCC. Ten patients (4.1%) experienced Clavien-Dindo Grade III complications. Seven patients(3.1%) developed recurrence at the ablation zone, and 11 (4.5%) developed recurrence elsewhere in the kidney. The 15-year local-recurrence- and disease-free survival were 96.5% and 88.6%, respectively. The 15-year metastasis-free survival and cancer-specific survival were 100%.
conclusionsRFA is a highly effective modality for the management of T1a RCC, with low complication and recurrence rates. Long-term data revealed favorable oncologic and survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.